We studied the in-hospital prognosis of 1105 patients who had their first transmural myocardial infarction; 611 patients (55.3%) had anterior myocardial infarction (AMI) and 494 (44.7%) had inferior myocardial infarction (IMI). Patients with IMI had a significantly lower in-hospital mortality rate (9.1% vs 15.6%, p = 0.0014) and significantly lower prevalences of congestive heart failure (39.4% vs 47.6%, p = 0.0066), cardiogenic shock (8.7% vs 12.6%, p = 0.0384) and conduction defects (left anterior hemiblock, right bundle branch block and intraventricular conduction defect). The patients with AMI had significantly higher peak enzyme levels, and a greater percentage of them (40.1% vs 25.9%) had SGOT >240 IU/l, whereas more patients with IMI (34.6% vs 27.8%) had SGOT <120 IU/I (p = 0.0001). When the parallel subgroups were compared according to the peak SGOT levels (<120, 120-240, and >240 IU/l, the differences in the mortality and morbidity between the two infarct locations diminished. However, patients with AMI still had a less favorable outcome. Logistic regression analysis demonstrated that both the peak enzyme level and the infarct location had an independent influence on the in-hospital prognosis of patients with first transmural infarction.
THE LOCATION of acute myocardial infarction (MI) has a significant influence on the patient's subsequent clinical course. Patients with inferior MI (IMI) have a significantly better prognosis'-9 and less myocardial damage9 10 than those with anterior MI (AMI). Goldberg and associates' concluded that the prognosis of patients was probably related to the extent of myocardial damage rather than to the MI location. By this reasoning, when allowance is made for the extent of myocardial injury or the amount of cardiac enzyme release, patients with MI regardless of the location would be expected to have a similar prognosis.
A recent report' demonstrating a worse prognosis of patients with AMI than those with IMI of similar infarct size indicated that the MI location itself may have an independent influence on the outcome of patients with acute MI. However, the finding of similar infarct size in patients with either MI location in this study9 differs from the findings of other reports,9 '0 which showed less myocardial damage associated with IMI. Furthermore, the influence of the enzyme release on the prognosis of patients with these two MI locations has not been fully investigated. Thus, we studied the in-hospital mortality and morbidity of patients with first transmural MI. The patients were stratified according to peak enzyme release to evaluate the independent contribution of MI location to the acute prognosis.
Materials and Methods
The population for this study was selected from 2231 patients who were admitted within 48 hours of acute MI to the Jewish or Barnes Hospital coronary care unit (CCU) between November 1971 and June 1975 , and between October 1975 and March 1978 Acute MI was diagnosed if two of the following criteria were present: compatible clinical history, typical pattern of serum enzyme elevations, and classic ECG changes indicative of transmural MI. All patients were admitted to the CCU for close surveillance and continuous cardiac monitoring for at least 3 days. A standard 12-lead ECG and serum enzyme levels were obtained for at least the first three consecutive days. The upper limit of normal for serum SGOT was 30 IU/l and for LDH was 205 IU/l. Demographic and clinical information was prospectively abstracted from each patient's chart as well as through direct patient interview by trained personnel according to a well-defined protocol." All records were subsequently transferred to a computerized data base.I The information was subjected to rigorous checks of consistency; when questions arose, the patients' charts were reviewed by a senior cardiologist.
The ECG diagnosis of transmural MI was based on pathologic Q waves (>0.04-second duration and >25% of R-wave amplitude) associated with evolving ST-segment and T-wave changes in the same leads or, in the case of posterior MI, by the presence of pathologic R waves (>0.04-second duration with RV,/SV, or RV,/SV, ¢ 1) associated with evolving ST-segment or T-wave changes in leads V, and V .'3 All patients with anteroseptal (Q waves in leads Vl 2), anterior (Q waves in leads V3), and lateral MIs (Q waves in leads V5-or I and aVL) were included in the group with AMI, and those with inferior (Q waves in leads II, III and aVE) or posterior MIs were included in the group with IMI.
Since the prognosis of acute MI is related to the total myocardial loss from all MIs rather than to the extent of the most recent MI,`4 the inclusion of patients with previous MI would make it difficult to interpret the relationship between the prognosis and the extent of myocardial damage. Furthermore, the ECG diagnosis of MI location in patients with previous Ml' or in those with nontransmural MI", 16 is subject to a substantial error. Therefore, only 1105 patients with first transmural MI were included in our study. Since the ECG diagnosis may not correspond to the pathologic findings,17 our study criteria could have excluded some transmural MI patients who did not have qualified Q waves and were classified as nontransmural MI. However, this probably involved only a few patients with each MI location and would not significantly influence our study.
The patients with either MI location were further divided into three subgroups according to peak SGOT levels: <120 IU/l (low), 120-240 IU/I (medium), and >240 Lu/l (high). These SGOT levels were chosen to separate patients with MI into subgroups of approximately equal numbers and were used in our previous analyses.'8'19 While many studies8 92021 have used creatine kinase and its isoenzymes to indicate the extent of MI, SGOT level has also been correlated with the amount of myocardial damage.22 Although SGOT may be released from extracardiac sources, it is a good predictor for prognosis of patients with ML. [23] [24] [25] [26] The in-hospital mortality and morbidity of patients within the two major groups (AMI and IMI) as well as the subgroups (stratified by peak SGOT) were compared. The following demographic and clinical features were selected for analysis as in our previous studies7-19 : (1) smoking at least one pack of cigarettes per day in the last 6 months before acute MI; (2) diagnosis of diabetes mellitus; (3) a history of hypertension, ascertained by the patient's assertion of a previous diagnosis by his physician; (4) cardiac arrhythmias and intraventricular conduction defects during the CCU stay, including sinus tachycardia, supraventricular premature complexes (SPCs), paroxysmal atrial tachycardia (PAT), atrial flutter or fibrillation, premature ventricular complexes (PVCs), atrioventricular (AV) blocks (first-degree, second-degree or complete), right bundle branch block (RBBB), left anterior or posterior hemiblocks (LAHB or LPHB), and non-specific intraventricular conduction defect (IVCD); (5) congestive heart failure during the CCU stay, diagnosed by the presence of pulmonary vascular redistribution or pulmonary congestion (mild or moderate) on chest radiograph with clinical findings of failure (rales or ventricular gallop), or marked pulmonary congestion or edema with or without clinical findings of failure; and (6) cardiogenic shock, defined as systolic blood pressure <90 mm Hg with evidence of peripheral vasoconstriction, including sweating, cold extremities, confused sensorium and low urinary output (<25 ml/hour).
Statistical analyses were performed with either a chi-square or Fisher's exact test when cell expectation fell below 5. The differences in the peak SGOT or LDH levels associated with the two MI locations were evaluated by t test of the log transform of the respective values. A two-tailed p value -0.05 was considered statistically significant.
We also used the odds ratio (W)27 to indicate the strength of association between the Ml location and clinical features. The odds ratio is closely related to the relative risk. When a clinical feature is associated with an increased risk in the presence of AMI, co is greater than 1; conversely, when the risk is decreased with AMI (i.e., increased with IMI), w is less than 1. A logistic regression analysis28 was used to determine whether the relationship between the Ml location and the clinical features (mortality or morbidity) remained after the patients were stratified by the enzyme level (SGOT or LDH).
Results
Of 2231 patients with acute Ml during the study period, 1105 who had definite first transmural Ml without previous infarct by history or evaluation of available ECGs were included in this study. Six hundred eleven patients (55.3%) had acute AMI and 494 (44.7%) had IMI. The distribution of age, sex and history of hypertension was similar in the two groups (table 1), but patients with AMI had a significantly higher prevalence of diabetes mellitus (p = 0.0185) and a lower prevalence of smoking history (p = 0.0474). Patients with AMI had significantly higher average peak SGOT (178 vs 157 IU/i, p = 0.0014) and LDH levels (696 vs 587 IU/i, p 0.00 13). When patients were divided into three subgroups according Abbreviation: MI = myocardial infarction.
to peak SGOT level, more patients with AMI were in the high peak SGOT group and more patients with IMI were in the low peak SGOT group (table 2) . The difference in the subgroup distribution between the two MI locations was highly significant statistically (p -0.0001).
The clinical course of patients in both groups are compared in table 3. The prevalences of cardiomegaly, SPCs, atrial flutter or fibrillation, PVCs and LPHB were similar in both groups. However, patients with AMI had a significantly higher mortality rate (15.6% vs 9.1%, p = 0.00 14) and significantly higher prevalences of congestive heart failure (47.6% vs 39.5%, p 0.0066) and cardiogenic shock (12.6% vs 8.7%. p -0.0384). In addition, the prevalences of sinus tachycardia, PAT, RBBB, LAHB and IVCD were also significantly higher in patients with AMI. As previously demonstrated,29 the prevalence of AV block was significantly higher in patients with IMI (27.9% vs 19.0%, p = 0.0004). Abbreviations: AV = atrioventricular; CHF = congestive heart failure; IVCD = intraventricular conduction defect: LAHB = left anterior hemiblock: LPHB = left posterior hemiblock; PAT paroxysmal atrial tachycardia; PVCs = premature ventricular complexes; RBBB = right bundle branch block: SPCs = supraventricular premature complexes.
When patients with comparable peak SGOT levels were compared (table 4), these differences were somewhat diminished. However, patients with IMI still had a more favorable in-hospital prognosis. In the low SGOT group, patients with IMI had a significantly lower prevalence of LAHB (co -3.67, p < 0.002) and substantially lower prevalences of PAT (w = 2.26) and IVCD (co = 2.61). In the medium SGOT group, the mortality rate and prevalences of sinus tachycardia, PAT, atrial flutter or fibrillation, LAHB and IVCD were significantly higher in patients with AMI. Patients with AMI also had a substantially higher prevalence of cardiogenic shock (w 2.29) and RBBB (w = 2.22). In the high SGOT group, patients with AMI had a substantially higher prevalence of LAHB (0) -7.55) and a significantly higher prevalence of sinus tachycardia (w -2.16, p < 0.001).
Patients with IMI who had medium or high SGOT levels had a significantly higher prevalence of AV block. Table 5 presents the results of the logistic regression analysis, which shows the independent contribution of one or more variables (peak SGOT or MI location) to the specified outcomes (mortality or morbidity). The chi-square values indicate the influence of a particular independent variable on the mortality or morbidity while controlling for the other. For example, after adjusting for whether an infarct is anterior, peak SGOT level is significantly related to the prevalence of cardiomegaly (x2 = 16.69, p = 0.0001). In contrast, after adjusting for peak SGOT level, whether an infarction is anterior does not have a significant relationship to the prevalence of cardiomegaly (X2 1.61, p > 0.20). The results of this logistic regression analysis show that both the peak SGOT level and the MI location have a significant independent relationship with mortality rate (p = 0.0001 and p -0.0052. respectively) and with the prevalences of congestive heart failure, sinus tachycardia, AV block, RBBB and IVCD. However, the prevalences of cardiomegaly, cardiogenic shock, SPCs, atrial flutter or fibrillation and PVCs were independent related only to the peak SGOT level, and the prevalence of LAHB was related only to the MI location.
When peak LDH instead of peak SGOT was used to stratify the patients. the findings were similar to those observed with the peak SGOT level. The in-hospital prognosis of patients with first transmural MI was independently related to the peak LDH level as well as the MI location.
Discussion
We and others -7 found that patients with IMI had a better in-hospital prognosis than those with AMI. They had a significantly lower mortality rate and significantly lower prevalences of poor left ventricular function (congestive heart failure and cardiogenic shock) and conduction defects (RBBB, LAHB and IVCD). Furthermore, the significantly lower enzyme release in our patients with IMI confirms several reports that demonstrated less myocardial damage9 !0 and better Although several investigators'-' have studied the influence of MI location on the prognosis of patients, the reason for the different clinical courses of patients with AMI and IMI has not been fully explained. The amount of myocardial damage exerts an important influence on the outcome of patients after Ml;'-33 this finding probably led Goldberg and associates3 to conclude that the smaller MI associated with IMI contributed to the better prognosis of this group of patients. However, if the poorer prognosis is related solely to the amount of myocardial damage, then controlling for the extent of MI or enzyme released should eliminate the differences in mortality and morbidity between the two MI locations. When we compared subgroups with comparable enzyme levels, the difference in the prognosis of these patients was somewhat diminished, but patients with AMI still had higher in-hospital mortality and morbidity. Our findings are in agreement with those of Strauss et al.,' who demonstrated a better prognosis of patients with IMI than those with AMI suffering a similar degree of myocardial injury. Thus, the MI location itself may independently affect the prognosis.
We used logistic regression analysis" to ascertain whether the in-hospital prognosis is independently related to both the MI location and the peak enzyme level. The results of this analysis show that both the peak enzyme level and the MI location made a significant independent contribution to the outcome of patients with first transmural MI. In general. the peak enzyme level appeared to have more influence on the prognosis, particularly on the mortality. indications of decreased left ventricular function (cardiomegaly, congestive heart failure, or cardiogenic shock), and the prevalence of atrial or ventricular dysrhythmias, whereas the prevalence of conduction defects was more related to the MI location.
We, as well as others,8 have proved that the cardiac enzyme release or infarct size index estimated from these enzymes alone cannot fully explain the less favorable outcome of AMI. The explanation for the independent contribution of the AMI location to the prognosis of acute MI is unknown. Bulkley34 suggested that the intrinsic and extrinsic qualitative differences between the anterior and inferior wall might have contributed to this different outcome. Patients with AMI are at greater risk for expansion, acute regional dilatation, and thinning of the infarct zone.35 In addition. left ventricular aneurysm, left ventricular thrombus, and myocardial rupture occur most often with infarcts of the anterior wall.1'0 36-37 Some of these potential complications may account for the independent influence of the AMI location on the prognosis of acute MI. However, the cardiac enzymes or infarct size index estimated from the enzymes may not reflect the true left ventricular damage in IMI, as a large percentage of these patients also have right ventricular damage. 31 19 The cardiac enzyme levels and infarct size index in this group of patients reflect injury to both ventricles. Sammel et al.40 demonstrated that patients with IMI had higher enzyme levels for a given degree of left ventricular damage estimated from the left ventriculogram than those with AMI. Therefore, even after adjustment for the enzyme levels or infarct size, patients with AMI may still have more left ventricular damage and a worse clinical outcome.
In conclusion, patients with first transmural AMI had a worse in-hospital prognosis than those with IMI, partially related to the higher cardiac enzyme release in AMI. However, the MI location itself appeared to make an independent contribution to the outcome of acute transmural MI unrelated to the enzyme levels, which may be attributed either to the potential complications of AMI or to the high incidence of right ventricular infarct associated with left ventricular damage in IMI.
